Cited by 148Intensive Care Unit Cognitive DisordersAnesthesia and Sedative AgentsAlcoholism and Thiamine Deficiency

Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis

Open access
Wu, Yi-Cheng, Tseng, Ping-Tao, Tu, Yu-Kang, Hsu, Chung-Yao, Liang, Chih-Sung, Yeh, Ta-Chuan, Chen, Tien-Yu, Chu, Che-Sheng +7 more·2019·JAMA Psychiatry

Abstract

Importance: Although several pharmacological interventions for delirium have been investigated, their overall benefit and safety remain unclear. Objective: To evaluate evidence regarding pharmacological interventions for delirium treatment and prevention. Data Sources: PubMed, Embase, ProQuest, ScienceDirect, Cochrane Central, Web of Science, ClinicalKey, and ClinicalTrials.gov from inception to May 17, 2018. Study Selection: Randomized clinical trials (RCTs) examining pharmacological interventions for delirium treatment and prevention. Data Extraction and Synthesis: To extract data according to a predetermined list of interests, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines were applied, and all meta-analytic procedures were conducted using a random-effects model. Main Outcomes and Measures: The primary outcomes were treatment response in patients with delirium and the incidence of delirium in patients at risk of delirium. Results: A total of 58 RCTs were included, in which 20 RCTs with 1435 participants (mean age, 63.5 years; 65.1% male) compared the outcomes of treatment and 38 RCTs with 8168 participants (mean age, 70.2 years; 53.4% male) examined the prevention of delirium. A network meta-analysis demonstrated that haloperidol plus lorazepam provided the best response rate for delirium treatment (odds ratio [OR], 28.13; 95% CI, 2.38-333.08) compared with placebo/control. For delirium prevention, the ramelteon, olanzapine, risperidone, and dexmedetomidine hydrochloride groups had significantly lower delirium occurrence rates than placebo/control (OR, 0.07; 95% CI, 0.01-0.66 for ramelteon; OR, 0.25; 95% CI, 0.09-0.69 for olanzapine; OR, 0.27; 95% CI, 0.07-0.99 for risperidone; and OR, 0.50; 95% CI, 0.31-0.80 for dexmedetomidine hydrochloride). None of the pharmacological treatments were significantly associated with a higher risk of all-cause mortality compared with placebo/control. Conclusions and Relevance: This network meta-analysis demonstrated that haloperidol plus lorazepam might be the best treatment and ramelteon the best preventive medicine for delirium. None of the pharmacological interventions for treatment or prophylaxis increased the all-cause mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2018.4365

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People with similar neuropathology show faster cognitive decline if they develop delirium than if they do not.

    “People with similar neuropathology show faster cognitive decline if they develop delirium than if they do not.284”

    From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [284]

    The introduction (section D; page unavailable) says delirium is associated with permanent cognitive decline. It does not compare the rate of decline in people with similar neuropathology who do and do not develop delirium; the paper instead examines pharmacological interventions for delirium. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wu, Y.-C., Tseng, P.-T., Tu, Y.-K., Hsu, C.-Y., Liang, C.-S., Yeh, T.-C., Chen, T.-Y., Chu, C.-S., Matsuoka, Y. J., Stubbs, B., Carvalho, A. F., Wada, S., Lin, P.-Y., Chen, Y.-W., & Su, K.-P.
Affiliations
  • Chang Gung Memorial Hospital (TW)
  • WinShine Clinics in Specialty of Psychiatry, Kaohsiung City, Taiwan
  • National Taiwan University (TW)
  • Kaohsiung Medical University (TW)
  • Tri-Service General Hospital (TW)
  • Kaohsiung Veterans General Hospital (TW)
  • National Cancer Centre Japan (JP)
  • National Health Service (GB)
  • Centre for Addiction and Mental Health (CA)
  • Chang Gung University (TW)
  • Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan
  • China Medical University (TW)
Corresponding author
Su, Kuan-Pin
Venue
JAMA Psychiatry
Published
2019-05-01
Volume
76
Issue
5
Pages
526
ISSN
2168-622X (ISSN-L)
OpenAlex
W2915429756
Cited by
148
References
50
Citations by year
2026: 9 · 2025: 23 · 2024: 11 · 2023: 25 · 2022: 24 · 2021: 23 · 2020: 25 · 2019: 8
FWCI
18.60
Type
journal article
Language
en
Open access
Locations
  • JAMA Psychiatry (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Anglia Ruskin Research Online (Anglia Ruskin University) (acceptedVersion)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • National Institute for Health and Care Research (ICA-CL-2017-03-001, NIHR-INF-0685)
  • Ministry of Science and Technology, Taiwan (MOST106-2314-B038-049, MOST106-2314-B039-027-MY3, NHRI-EX105-10528NI, MOST 106)
  • National Health Research Institutes (DMR-107-091, NHRI-EX105-10528NI, CRS-106-063, DMR-107-204, CRS-106-063, DMR-107-202, DRM-107-097, DMR-107-202, EX105)
  • China Medical University
  • China Medical University, Taiwan (DMR-107-091, DMR-107-202, CRS-106-063, DMR-107-204, DRM-107-097)
  • Division of Materials Research
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
  • Health Sciences › Medicine › Neurology › Alcoholism and Thiamine Deficiency
Keywords
delirium, delirium prevention, pharmacological interventions, treatment response, drug safety, haloperidol, lorazepam, ramelteon, olanzapine, risperidone, dexmedetomidine, antipsychotic drugs, benzodiazepines, adverse effects, delirium incidence, older adults, critically ill patients
MeSH terms
Network Meta-Analysis, Delirium, Drug Therapy, Combination, Haloperidol, Humans, Indenes, Lorazepam, Antipsychotic Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review